February 2023 PVRI Community Call with Jason Zelt

28 February 2023

In this Community Call, we discussed:

G9a/GLP Targeting Ameliorates Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension
Right Ventricular Maladaptation to Pressure Overload in Fischer Rats is Associated with Profound Deficiency in Adenylate Kinase 1 and Impaired Ventricular Energetics
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression

Jason Zelt, Community Call Guest

Jason Weatherald, Community Call Host

Charifa Awada, Community Call Host

Tatiana Kudryashova, Community Call Host

Katrina Barry, Community Call Host

Other materials on this topic

9 May 2024

Chromosome dynamics in pulmonary hypertension: mechanism and new treatments

Webinar presentations:

Chromatin remodelling and enhancer distance in pulmonary arterial hypertension
Identification of novel candidate genes and variants associated with PAH and new technologies based on episignature for PAH confirmation
Chromosomal aberrations in pulmonary arterial hypertension

Members Only

22 April 2024

Early identification of SOX17 deficiency in infants to guide management of heritable pulmonary arterial hypertension using PDA stent to create reverse Potts shunt physiology

Heritable pulmonary arterial hypertension (HPAH) is a rare progressive condition that includes patients with an identified genetic cause of pulmonary arterial hypertension (PAH)...

Pulmonary Circulation

12 March 2024

Unlocking the potential of genetic research in pulmonary arterial hypertension: Insights from clinicians, researchers, and study team

Genetic research and testing are increasingly important for understanding and treating pulmonary arterial hypertension. We aimed to explore how attitudes toward genetic research among clinical and research teams...

Pulmonary Circulation

7 March 2024

An inverse causal relationship between serum 25-hydroxyvitamin D levels and pulmonary hypertension: A two-sample Mendelian randomization study

Observational studies have confirmed that 25-hydroxyvitamin D (25(OH)D) is associated with pulmonary hypertension (PH), but the causal association between each other is unclear. Therefore, Mendelian randomization (MR) method was performed to...

Pulmonary Circulation

Additional comments are available to members. Login or register to become a member today

RegisterorLogin to view

February 2023 PVRI Community Call with Jason Zelt

Featuring

Chromosome dynamics in pulmonary hypertension: mechanism and new treatments

Early identification of SOX17 deficiency in infants to guide management of heritable pulmonary arterial hypertension using PDA stent to create reverse Potts shunt physiology

Unlocking the potential of genetic research in pulmonary arterial hypertension: Insights from clinicians, researchers, and study team

An inverse causal relationship between serum 25-hydroxyvitamin D levels and pulmonary hypertension: A two-sample Mendelian randomization study

More from PVRI Community Calls